Nkarta (NKTX) Assets Average (2020 - 2026)
Nkarta's quarterly Assets Average came in at $388.1 million in Q1 2026, down 20.12% year-on-year from $485.9 million in Q1 2025, and down 6.63% quarter-over-quarter from $415.7 million in Q4 2025.
Nkarta has reported Assets Average for 7 years, with the latest figure at $388.1 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 20.12% year-over-year to $388.1 million; the trailing twelve-month figure through Mar 2026 stood at $388.1 million (down 20.12% YoY), and the FY2025 full-year result was $452.7 million, up 2.88% from the prior year.
- Assets Average for Q1 2026 stood at $388.1 million, down from $415.7 million in the prior quarter.
- The five-year high for Assets Average was $565.5 million in Q2 2024, with the low at $290.1 million in Q1 2022.
- Average Assets Average over 5 years is $452.7 million, with a median of $459.5 million recorded in 2025.
- Year-over-year, Assets Average jumped 72.46% in 2022 and slipped 20.12% in 2026.
- Tracing NKTX's Assets Average over 5 years: stood at $488.4 million in 2022, then fell by 19.66% to $392.4 million in 2023, then jumped by 31.66% to $516.6 million in 2024, then decreased by 19.53% to $415.7 million in 2025, then dropped by 6.63% to $388.1 million in 2026.
- The last three Assets Average figures came in at $388.1 million (Q1 2026), $415.7 million (Q4 2025), and $437.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 388.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 388.14 Mn |
| Dec 31, 2025 | 415.72 Mn |
| Sep 30, 2025 | 437.77 Mn |
| Jun 30, 2025 | 459.46 Mn |
| Mar 31, 2025 | 485.91 Mn |
| Dec 31, 2024 | 516.62 Mn |
| Sep 30, 2024 | 543.06 Mn |
| Jun 30, 2024 | 565.51 Mn |
| Mar 31, 2024 | 477.91 Mn |
| Dec 31, 2023 | 392.37 Mn |
| Sep 30, 2023 | 417.45 Mn |
| Jun 30, 2023 | 443.60 Mn |
| Mar 31, 2023 | 465.55 Mn |
| Dec 31, 2022 | 488.37 Mn |
| Sep 30, 2022 | 503.72 Mn |
| Jun 30, 2022 | 404.97 Mn |
| Mar 31, 2022 | 290.10 Mn |
| Dec 31, 2021 | 283.18 Mn |
| Sep 30, 2021 | 300.79 Mn |
| Jun 30, 2021 | 317.40 Mn |
| Mar 31, 2021 | 331.67 Mn |
| Dec 31, 2020 | 344.97 Mn |
| Sep 30, 2020 | 197.96 Mn |